Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib for refractory arterio-venous malformations
2022-501830-47-01Phase 2Authorised
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in arteriovenous malformation (AVM), sponsored by Cliniques universitaires Saint-Luc. Primary endpoints: Quality of life improvement, Symptom evaluation focused on pain and 1 more. Planned start Apr 2025; status: authorised.
02
Drugs
regorafenib
03
Conditions
arteriovenous malformation (AVM)
Beyond the preview
Go deeper on 2022-501830-47-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501830-47-01.